MeiraGTx Holdings PLC MGTX
News
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MeiraGTx Shares Rise Premarket on Ophthalmology Collaboration With Eli Lilly


